Trial Profile
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders; Ulcer
- Focus Therapeutic Use
- Sponsors Beijing Northland Biotech
- 23 Mar 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Dec 2014 New trial record